#	#5							
ete if Known	크							
9/855,342	0							
	Ŧ	S	m					

<u>. </u>								
Substitute for	or form 14	449A/PTO	SEP 1 0	2004	-	Complete if Known		
			1	, Z001	Application Number	09/855,342		
	INFO	RMA.	LIGN	ع ا			7	դ r
	DISC	CLOS	URIK & TRAD	EMART	Filing Date	May 14, 2001		5tp (
STATE	MEN	T BY	APPLICA	NT [First Named Inventor	Caligiuri	럶	—՝ г
					Group Art Unit	5 2 2646 1642		
(U.	se as man	y sheets a	s necessary)		Examiner Name	Not yet assigned	9 8	7001
Sheet	1		of		Attorney Docket Number	35784/209112 (5784-50)	=
					· · · · · · · · · · · · · · · · · · ·		1 500 5 5784-50) 7390	
				U.	S. PATENT DOCUMEN	NTS		
		U	J.S. Patent Docu	ment		Date of	Pages, Columns, Li	ines,
Examiner Cite Initials* No.1		Kind Co Number (if know				icant Publication of Cited Document MM-DD-YYYY	Where Relevant Passages of Relevant Figures Appear	
	•							
						· · · · · · · · · · · · · · · · · · ·		
	<u> </u>	-		-				
	 	<u> </u>		+				
		ļ	···					
		1					<u> </u>	
		 		 			- 	
		ļ						
	L	-1	FC	REIC	GN PATENT DOCU	MENTS		
	<u> </u>	For	reign Patent Doo		<u> </u>	Date of	Pages, Columns, Lines,	$\overline{}$
Examiner	Cite	· ·	1	Kind Coc		Publication of	Where Relevant	1/4
Initials	No.	Office'	Number ⁴ (i	f known)	Applicant of Cited Docum	· · · · · · · · · · · · · · · · · · ·	Passages of Relevant Figures Appear	
SP	1	EP	0 256 714	A2	Cetus Corporation	02-24-1988		
0/								
32	2	WO	89/06692	A1	Genentech, Inc.	07-27-1989		-
								+
				<u> </u>	<u> </u>			
								†
			 					+
								+
	ļ			_				
Examiner			1-			Date	1/24/03	
Signature	1		ν			Considered	1/027/00	

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Unique citation designation number.
 See attached Kinds of U.S. Patent Documents.

³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible.

⁶ Applicant is to place an "X" here if English language Translation is attached.

			2			1				
		SED	1 0 2004	8)		<u> </u>				
Substitute for form 1449A/PTO			1 0 2001		mplete if Known		7			
\ <u>\</u>				Application Number	09/855,342	G 7				
INFORMATION TRADEMAN			PADEMARK	Filing Date	May 14, 2001	S	<u>,</u> 1			
			MADE			- E	╮ ∐			
STATE	MEN ⁷	r by appli	CANT	First Named Inventor	Caligiuri					
				Group Art Unit 5	1646 1642	1600	3 1			
(Us	e as many	sheets as necessar	'y)	Examiner Name	Not yet assigned	29	τ			
Sheet	2	of	2	Attorney Docket Number	35784/209112 (5784	1-50) 8				
			NON PAT	TENT LITERATURE DOCU	MENTS					
		Include nam	ne of the auth	or (in CAPITAL LETTERS), title of t	he article (when appropriate)	, title of the item				
Examiner Initials	Cite No.	(book, maga	azine, journal	, serial, symposium, catalog, etc.), da	te, page(s), volume-issue nur	mber(s), publisher	, T			
mitiais	100.		Country wher	al. (1999) "Fc Receptor Cross-	Linking in the Presence	of.				
				otent Stimulus to Natural Kille						
50		Implication	ons for An	ti-Her2 Antibody Therapy." Pr	oceedings of the Ameri	ican				
7	`				i-Her2 Antibody Therapy," Proceedings of the American cer Research 40: 77 (XP002171956)					
	4			999) "Phase I Trial of Recomb		Monoclonal	***************************************			
		Antibody	(H) Plus I	Low-Dose Interleukin-2 (IL-2)	in Patients with Solid T	Cumors,"				
1				Annual Meeting of the America	in Society for Clinical (Oncology 18:				
			<u>200101037</u>							
- 1	5		KI et al. (1	1996) "Growth Inhibition of Bi	reast Cancer Cell Lines	by				
1		Combinat	ions of An	ti-P185 ^{Her2} Monoclonal Antibo	ody and Cytokines," An	ticancer				
				36 (XP000973070)			_			
1	6	LI et al. (1999) "Pre	paration and Characterization	of a Human Interleukin	1-2 and Anti-				
				Fusion Protein," <i>Proceedings of</i> 2: 358 (XP002171954)	j ine American Associa	tion for				
	7				Antibody Interleukin)				
	'	1 \	LI et al. (2000) "Chemical Conjugation of a Novel Antibody-Interleukin 2 Immunoconjugate Against c-erbB-2 Product," Chinese Medical Journal 113: 151-153							
		(XP00092	(XP000925246)							
	8		TAGLIAFERRI et al. (1996) "Differential Sensitivity to Non-Major Histocompatibility							
- 1		Complex-	Complex-Restricted Recombinant Interleukin 2-Activated Lymphocyte Killing of							
		Human M	lammary E	pithelial MCF-10A Cells Over	expressing Oncogenes	or Protein				
		Kinase A	Kinase A Subunits," Clinical Cancer Research 2: 207-214 (XP002171953)							
	9	WEINER	et al. (199	95) "Clinical Development of 2	B1, A Bispecific Murir	ne Monoclonal				
Ψ				c-erbB-2 and Fc-gamma-RIII,	" Journal of Hematothe	erapy 4: 453-				
······································	1,4		02048529							
OR	10	Question	is and Ans	wers about NCI's Expanded Re	esearch with Herceptin	(R)," National				
5 R		ITRI :bttp	Sillule, Da Urov poi p	ckgrounders, Online! Betheso ih.gov/massmedia/back, pp. 1	8 (VD002171055)	1998)				
		SR	.,, ICATIONH	III.507/IIIaoseneura/Uack, pp. 1	ʊ (ʌ፲-ʊʊɛː / 1733)					

Examiner Signature	10-	Date Considered	1/24/03
		00110100	

^{*}Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

			'					. 4-	,
<i>Y</i> o					, ,	Political State of the State of		#	6
Substitute f	or form 14	149A/PT	0				plete if Known	DEAT	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)					Ap	plication Number	09/855,342	<u> </u>	IV
£0	INFO	RMA	TION	•				CED O	
- NE	DISC	CLOS	URE		Fili	ing Date	May 14, 2001	SEP 2 6	<u> 200</u>
STATE	CMEN'	T BY	APPLIC	CANT	Fire	st Named Inventor	Caligiuri		
					Gro	oup Art Unit 5th	1646 1642	TECH CENTER	1600
(0	se as man	y sheets	as necessary)	<i>.</i>	Exa	aminer Name	Not yet assigned	i	
Sheet	1		of	1	Att	orney Docket Number	35784/209112 (5784-50)	
	Τ				S. P	ATENT DOCUMENTS	S		
Examiner	Cite] !	U.S. Patent D	Ocument Kind Co	de ²	Name of Patentee or Applicant	Date of	Pages, Columns, Li Where Relevant Passa	
Initials*	No.1	1 1		Of Cited Document			ant Figures Appear		
	ļ	<u> </u>			·		MM-DD-YYYY		
			******						•
		<u> </u>							
.	<u>.L</u>			FORE		N PATENT DOCUME	VTS	<u> </u>	
		Fc	oreign Patent			VITALENT DOCUMEN	Date of	Pages, Columns, Lines,	1
Examiner	Cite		3 4	Kind C			Publication of	Where Relevant	T ⁶
Initials	No.	Office	Number*	(if know	n) ³	Applicant of Cited Document	Cited Document	Passages or Relevant Figures Appear	
	<u> </u>						MM-DD-YYYY		
	 								
	T					LITERATURE DOCU			
Examiner	Cite	Include	e name of the	author (in	CAPI	TAL LETTERS), title of the artic	le (when appropriate),	, title of the item	
Initials	No.	and/or	magazine, jo country when	uman, sema re publishe	u, sym d.	nposium, catalog, etc.), date, page	(s), volume-issue nur	nber(s), publisher, city	T
	11					ily Subcutaneous Injection	of Low-Dose Inte	erleukin 2	
SR		Expa	nds Natura	l Killer (Cells	in Vivo Without Significan	t Toxicity," Clin.	Cancer Res. 2:	
`		669-6	577.						
	12	MER	OPOL et a	d. (1998)	"Ev	aluation of Natural Killer (Cell Expansion and	d Activation in	
4		Vivo with Daily Subcutaneous Low-Dose Interleukin-2 Plus Periodic Intermediate-Dose Pulsing," Cancer Immunol. Immunother 46: 318-326.							
		ruisii	ig, Cance	rımmun	OI. 11	nmunotner 40: 318-326.	**************************************		
	1	ı							1

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Date

Considered

1/24/03

RTA01/2103788v1

Examiner

Signature

¹ Unique citation designation number.

² See attached Kinds of U.S. Patent Documents.

³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible.
 Applicant is to place an "X" here if English language Translation is attached.